Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lacnotuzumab - Novartis Oncology

Drug Profile

Lacnotuzumab - Novartis Oncology

Alternative Names: Anti-M-CSF-antibody; MCS-110

Latest Information Update: 10 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Dana-Farber Cancer Institute; Novartis; Novartis Oncology; Seoul National University Hospital
  • Class Anti-inflammatories; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Macrophage colony stimulating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Giant cell tumour of tendon sheath; Pigmented villonodular synovitis; Triple negative breast cancer
  • Phase I/II Malignant melanoma; Solid tumours
  • Discontinued Bone metastases; Prostate cancer

Most Recent Events

  • 06 Feb 2023 Novartis terminates a phase Ib trial in Triple negative Breast cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or grater) in USA, Australia, Hong Kong, Israel, Italy, Japan, Netherlands, Singapore and Spain (IV, infusion), based on sponsored decision (NCT03742349)
  • 28 Feb 2022 No recent reports of development identified for phase-I development in Triple negative Breast-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Israel, Spain, Netherlands, Japan, Italy, Hong Kong, Australia, USA (IV, Infusion)
  • 10 Apr 2021 Efficacy and pharmacodynamics data from a phase I/II trial in Solid tumours presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top